Recordati Overview
- Year Founded
-
1926
- Status
-
Public
- Employees
-
4,700
- Stock Symbol
-
REC
- Investments
-
24
- Share Price
-
$57.87
- (As of Thursday Closing)
Recordati General Information
Description
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
Contact Information
Website
www.recordati.comCorporate Office
- Via Matteo Civitali, 1
- 20148 Milan
- Italy
Corporate Office
- Via Matteo Civitali, 1
- 20148 Milan
- Italy
Recordati Stock Performance
As of 19-Nov-2026, Recordati’s stock price is $57.87. Its current market cap is $12B with 208M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $57.87 | $58.04 | $50.16 - $62.10 | $12B | 208M | 446K | $2.98 |
Recordati Financials Summary
As of 30-Sep-2026, Recordati has a trailing 12-month revenue of $3.21B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 14,404,213 | 14,073,863 | 12,267,524 | 12,805,873 |
| Revenue | 3,213,607 | 2,953,552 | 2,533,798 | 2,253,239 |
| EBITDA | 1,161,300 | 1,000,537 | 861,086 | 766,719 |
| Net Income | 609,326 | 500,411 | 450,703 | 421,159 |
| Total Assets | 6,188,915 | 6,169,421 | 5,342,770 | 4,651,667 |
| Total Debt | 2,497,411 | 2,898,356 | 2,585,225 | 1,999,558 |
Recordati Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Recordati Comparisons
Industry
Financing
Details
Recordati Competitors (66)
One of Recordati’s 66 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Grifols | Corporation | Barcelona, Spain | ||||
| Eisai Europe | Corporation | Hatfield, United Kingdom | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Shionogi | Corporation | Osaka, Japan |
Recordati Patents
Recordati Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4389746-A2 | P2x3 receptor antagonists | Inactive | 21-Dec-2022 | ||
| EP-4389746-A3 | P2x3 receptor antagonists | Inactive | 21-Dec-2022 | ||
| WO-2024133200-A1 | P2x3 receptor antagonists | Inactive | 21-Dec-2022 | ||
| WO-2024133200-A4 | P2x3 receptor antagonists | Inactive | 21-Dec-2022 | ||
| EP-4316468-A1 | Innovative complexation of lipido-sterolic serenoa extract with tadalafil | Active | 03-Aug-2022 | A61K9/143 |
Recordati Signals
Recordati Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Recordati Investments & Acquisitions (24)
Recordati’s most recent deal was a Merger/Acquisition with EUSA Academic Internship Experts for . The deal was made on 30-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EUSA Academic Internship Experts | 30-Apr-2026 | Merger/Acquisition | Educational and Training Services (B2C) | ||
| STRM.BIO | 07-Jan-2026 | Seed Round | Drug Discovery | ||
| Sanofi (Global Rights to Enjaymo) | 29-Nov-2024 | Buyout/LBO | Buildings and Property | ||
| EUSA Pharma (UK) | 16-Mar-2022 | Merger/Acquisition | Pharmaceuticals | ||
| Novartis (Signifor,Signifor LAR and Osilodrostat) | 23-Oct-2019 | Corporate Asset Purchase | Buildings and Property |
Recordati ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
23.98 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Recordati Exits (1)
Recordati’s most recent exit was on 01-Jan-1986 from Technogenetics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Technogenetics | 01-Jan-1986 | Completed |
|
Recordati Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| EUSA Pharma (UK) | Hemel Hempstead, United Kingdom | 2006 | |
| Recordati Polska | Warsaw, Poland | 2000 | |
| Natural Point | Milan, Italy | 1993 | |
| Recordati Rare Diseases | Puteaux, France | 1990 | |
| Orphan Europe | Puteaux, France | 1990 |
Recordati FAQs
-
When was Recordati founded?
Recordati was founded in 1926.
-
Where is Recordati headquartered?
Recordati is headquartered in Milan, Italy.
-
What is the size of Recordati?
Recordati has 4,700 total employees.
-
What industry is Recordati in?
Recordati’s primary industry is Pharmaceuticals.
-
Is Recordati a private or public company?
Recordati is a Public company.
-
What is Recordati’s stock symbol?
The ticker symbol for Recordati is REC.
-
What is the current stock price of Recordati?
As of 19-Nov-2026 the stock price of Recordati is $57.87.
-
What is the current market cap of Recordati?
The current market capitalization of Recordati is $12B.
-
What is Recordati’s current revenue?
The trailing twelve month revenue for Recordati is $3.21B.
-
Who are Recordati’s competitors?
Novartis, Grifols, Eisai Europe, Cipla, and Shionogi are some of the 66 competitors of Recordati.
-
What is Recordati’s annual earnings per share (EPS)?
Recordati’s EPS for 12 months was $2.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process